In one paragraphArticle in The Journal of infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
27 authors.
Nelly AmenyogbeDepartment of Microbiology and Immunology, Dalhousie University, Halifax, Nova Scotia, Canada.ORCID 0000-0002-7817-1534 Rym Ben-OthmanChronic Disease Theme, Kids Research Institute of Australia, Perth, Washington, Australia.ORCID 0000-0002-7245-6854 Bing CaiDepartment of Pediatrics, BC Children's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.ORCID 0000-0002-3632-9866 Mandy LoDepartment of Pediatrics, BC Children's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.ORCID 0000-0003-3457-8794 Olubukola T IdokoVaccines and Immunity Theme, Medical Research Council Unit The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, The Gambia.ORCID 0000-0002-8802-2946 Oludare A OdumadePrecision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, Massachusetts, USA.ORCID 0000-0002-8630-8510 Reza FalsafiDepartment of Microbiology and Immunology, University of British Columbia, Vancouver, British Columbia, Canada.
Travis M BlimkieMolecular Biology and Biochemistry, Simon Fraser University, Burnaby, British Columbia, Canada.ORCID 0000-0001-8778-8627 Andy AnDepartment of Microbiology and Immunology, University of British Columbia, Vancouver, British Columbia, Canada.ORCID 0000-0001-9777-4456 Casey P ShannonPROOF Centre of Excellence, Providence Research, Vancouver, British Columbia, Canada.ORCID 0000-0002-5687-3156 Bhavjinder K DhillonDepartment of Microbiology and Immunology, University of British Columbia, Vancouver, British Columbia, Canada.
Joann Diray-ArcePrecision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, Massachusetts, USA.ORCID 0000-0003-2183-4269 Al OzonoffPrecision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, Massachusetts, USA.ORCID 0000-0003-4233-5899 Kinga K SmolenPrecision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, Massachusetts, USA.ORCID 0000-0001-8650-3693 Kerry McEnaneyPrecision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, Massachusetts, USA.ORCID 0000-0002-0378-3456 Asimenia AngelidouPrecision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, Massachusetts, USA.ORCID 0000-0002-6716-6561 Peter RichmondChronic Disease Theme, Kids Research Institute of Australia, Perth, Washington, Australia.ORCID 0000-0001-7562-7228 Scott J TebbuttPROOF Centre of Excellence, Providence Research, Vancouver, British Columbia, Canada.ORCID 0000-0002-7908-1581 Beate KampmannVaccines and Immunity Theme, Medical Research Council Unit The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, The Gambia.ORCID 0000-0002-6546-4709 Robert E W HancockDepartment of Microbiology and Immunology, University of British Columbia, Vancouver, British Columbia, Canada.ORCID 0000-0001-5989-8503 Amy H Y LeeMolecular Biology and Biochemistry, Simon Fraser University, Burnaby, British Columbia, Canada.ORCID 0000-0003-3250-3246 Ofer LevyPrecision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, Massachusetts, USA.ORCID 0000-0002-5859-1945 Tobias R KollmannChronic Disease Theme, Kids Research Institute of Australia, Perth, Washington, Australia.ORCID 0000-0003-2403-9762 David MartinoChronic Disease Theme, Kids Research Institute of Australia, Perth, Washington, Australia.ORCID 0000-0001-6823-4696 Funding
Transcriptomics to define biomarkers of neonatal vaccine immunogenicityU19AI118608 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI LEVY, OFER · 2017 to 2021
$24.7MProteomics and Metabolomics Core: IDEAL shapes vaccine response, susceptibility to respiratory infectious disease and asthmaU19AI168643 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI OFER LEVY · 2022 to 2026
$10.0MImmunometabolic signatures of BCG-induced neonatal trained immunityK08AI168487 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Asimenia Angelidou · 2023 to 2026
$704kAngelidou LabCIHRHuman Immunology Project Consortium U19A11608IDEAL U19AI168643Mentored Clinical Scientist Development 1K08AI168487National Institute of Allergy and Infectious DiseasesNIAID NIH HHS K08 AI168487NIAID NIH HHS U19 AI118608NIAID NIH HHS U19 AI168643NIH HHSR. E. W. H.University of British Columbia Killam
6 · The paper itselfAbstract
We investigated the genetic and epigenetic regulation of the UBASH3A gene and its association with early-onset sepsis. Using matched whole blood DNA methylation, gene expression, genotypes, and immune cell counts from the EPIC-HIPC newborn cohort, we report that promoter methylation was negatively correlated (Pearson r = -0.5, P < 2.2 × 10-16) with ontogenetic changes in UBASH3A gene expression and circulating CD3+ T-cell numbers. Higher promoter methylation at birth was associated with lower UBASH3A expression and reduced early-onset sepsis risk (odds ratio, 0.26; P = .015). Genetic variation significantly influenced variations in baseline UBASH3A methylation (132 cis-meQTL, false discovery rate <0.05).
Indexed as
Adaptor Proteins, Signal TransducingDNA MethylationGenetic Predisposition to DiseasePromoter Regions, GeneticSepsisT-LymphocytesEpigenesis, GeneticFemaleHumansInfant, NewbornMaleAdaptor Proteins, Signal TransducingDNA methylationneonatal sepsisontogenyUBASH3A
Identifiers
PMID41408597
PMCPMC13017222
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390